352 related articles for article (PubMed ID: 10739116)
1. Localization of the 1,4-dihydropyridine drug acceptor of P-glycoprotein to a cytoplasmic domain using a permanently charged derivative N-methyl dexniguldipine.
Ferry D; Boer R; Callaghan R; Ulrich WR
Int J Clin Pharmacol Ther; 2000 Mar; 38(3):130-40. PubMed ID: 10739116
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the dexniguldipine binding site in the multidrug resistance-related transport protein P-glycoprotein by photoaffinity labeling and mass spectrometry.
Borchers C; Boer R; Klemm K; Figala V; Denzinger T; Ulrich WR; Haas S; Ise W; Gekeler V; Przybylski M
Mol Pharmacol; 2002 Jun; 61(6):1366-76. PubMed ID: 12021398
[TBL] [Abstract][Full Text] [Related]
3. Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine.
Ferry DR; Malkhandi PJ; Russell MA; Kerr DJ
Biochem Pharmacol; 1995 Jun; 49(12):1851-61. PubMed ID: 7598747
[TBL] [Abstract][Full Text] [Related]
4. Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells.
Malkhandi J; Ferry DR; Boer R; Gekeler V; Ise W; Kerr DJ
Eur J Pharmacol; 1994 Dec; 288(1):105-14. PubMed ID: 7705462
[TBL] [Abstract][Full Text] [Related]
5. B9209-005, an azido derivative of the chemosensitizer dexniguldipine-HCl, photolabels P-glycoprotein.
Borchers C; Ulrich WR; Klemm K; Ise W; Gekeler V; Haas S; Schödl A; Conrad J; Przybylski M; Boer R
Mol Pharmacol; 1995 Jul; 48(1):21-9. PubMed ID: 7623771
[TBL] [Abstract][Full Text] [Related]
6. Functional studies of P-glycoprotein in inside-out plasma membrane vesicles derived from murine erythroleukemia cells overexpressing MDR 3. Properties and kinetics of the interaction of vinblastine with P-glycoprotein and evidence for its active mediated transport.
Schlemmer SR; Sirotnak FM
J Biol Chem; 1994 Dec; 269(49):31059-66. PubMed ID: 7983045
[TBL] [Abstract][Full Text] [Related]
7. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.
Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
Biol Pharm Bull; 1999 Dec; 22(12):1355-9. PubMed ID: 10746169
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site.
Ferry DR; Russell MA; Cullen MH
Biochem Biophys Res Commun; 1992 Oct; 188(1):440-5. PubMed ID: 1358068
[TBL] [Abstract][Full Text] [Related]
9. Indoloquinoxaline compounds that selectively antagonize P-glycoprotein.
Smith CD; Myers CB; Zilfou JT; Smith SN; Lawrence DS
Oncol Res; 2000; 12(5):219-29. PubMed ID: 11417747
[TBL] [Abstract][Full Text] [Related]
10. BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
Liu Z; Lheureux F; Pouliot JF; Heckel A; Bamberger U; Georges E
Mol Pharmacol; 1996 Sep; 50(3):482-92. PubMed ID: 8794885
[TBL] [Abstract][Full Text] [Related]
11. Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
Callaghan R; Higgins CF
Br J Cancer; 1995 Feb; 71(2):294-9. PubMed ID: 7841043
[TBL] [Abstract][Full Text] [Related]
12. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells.
Tamai I; Safa AR
J Biol Chem; 1991 Sep; 266(25):16796-800. PubMed ID: 1679434
[TBL] [Abstract][Full Text] [Related]
13. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.
Dale IL; Tuffley W; Callaghan R; Holmes JA; Martin K; Luscombe M; Mistry P; Ryder H; Stewart AJ; Charlton P; Twentyman PR; Bevan P
Br J Cancer; 1998 Oct; 78(7):885-92. PubMed ID: 9764579
[TBL] [Abstract][Full Text] [Related]
14. N-(p-azido-3-[125I]iodophenethyl)spiperone binds to specific regions of P-glycoprotein and another multidrug binding protein, spiperophilin, in human neuroblastoma cells.
Safa AR; Agresti M; Bryk D; Tamai I
Biochemistry; 1994 Jan; 33(1):256-65. PubMed ID: 7904476
[TBL] [Abstract][Full Text] [Related]
15. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
[TBL] [Abstract][Full Text] [Related]
16. Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles.
Horio M; Lovelace E; Pastan I; Gottesman MM
Biochim Biophys Acta; 1991 Jan; 1061(1):106-10. PubMed ID: 1671642
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents.
Pascaud C; Garrigos M; Orlowski S
Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):351-8. PubMed ID: 9657975
[TBL] [Abstract][Full Text] [Related]
18. Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.
Shi Z; Jain S; Kim IW; Peng XX; Abraham I; Youssef DT; Fu LW; El Sayed K; Ambudkar SV; Chen ZS
Cancer Sci; 2007 Sep; 98(9):1373-80. PubMed ID: 17640301
[TBL] [Abstract][Full Text] [Related]
19. Reversal of vinblastine resistance in human leukemic cells by haloperidol and dihydrohaloperidol.
Kataoka Y; Ishikawa M; Miura M; Takeshita M; Fujita R; Furusawa S; Takayanagi M; Takayanagi Y; Sasaki K
Biol Pharm Bull; 2001 Jun; 24(6):612-7. PubMed ID: 11411546
[TBL] [Abstract][Full Text] [Related]
20. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment.
Jetté L; Murphy GF; Béliveau R
Int J Cancer; 1998 May; 76(5):729-37. PubMed ID: 9610733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
